Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis
Main Author: | |
---|---|
Publication Date: | 2011 |
Other Authors: | , , , , , , |
Format: | Article |
Language: | por |
Source: | Brazilian Journal of Transplantation |
Download full: | https://bjt.emnuvens.com.br/revista/article/view/200 |
Summary: | Purpose: Thymoglobulin is an important polyclonal antibody used in kidney transplantation as an induction therapy, and it has been asso- ciated to a decrease in delayed graft function and acute rejection rates. The authors used a paired kidney analysis to compare thymoglobulin with other induction therapies, in order to minimize the donor variabilility and bias. Methods: All paired kidneys from deceased donors during the period 2006-2008, where one kidney was allocated to a patient receiving thymoglobulin (group1) and its mate allocated to a pa- tient receiving anti IL-2R monoclonal antibodies (group 2) were assessed in this retrospective study. To investigate the impact of induction therapy, we investigated the delayed graft function rates (DGF), acute rejection (AR) and renal function in the first year after the transplant (Tx) in the paired kidney subjects. Results: A total of 94 Txs were investigated: mean age: 38.4 years, being 60.6 % male and with average dialysis time of 4.11 yrs. No statistically significant difference was found between both groups in relation to the recipient age, gender, HLA mismatches, PRA, cold ischemia time (CIT). Immunosuppressive protocol consisted to mofetil mycophenolate plus calcineurin inhibitors (tacrolimus in 88.3% of patients) in both groups, and steroids in 62% of patients. Deceased donor characteristics were: 63.8% male, mean age 30.9 ys, serum creatinine 1.17 mg/dl. The most important causes of death were trauma in 48.9% and cerebrovascular accident in 19.1% donors. The magnitude of renal function at 3, 6 and 12 post-Tx months and the DGF rate (56.6% vs 63.0%) were not statistically different between both groups. The rate of any AR report within 1 post-Tx year was significantly lower in the Thymo group (19.6 vs 45.7%; p = 0.008), and the incidence of CMV disease was similar in both groups (10.9 vs 15.2%; p = 0.535). Conclusion: Thymoglobulin was associated to a significant reduction in 1 yr-acute rejection rate in this cohort of paired kidneys, but without presenting a decreased DGF rate. There was no impact on renal function/CMV disease in the 1st post-Tx year. |
id |
ABTO_94f2f0a3ae9a1418f5ff05e39c499893 |
---|---|
oai_identifier_str |
oai:ojs3.emnuvens.com.br:article/200 |
network_acronym_str |
ABTO |
network_name_str |
Brazilian Journal of Transplantation |
repository_id_str |
|
spelling |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysisTERAPIA DE INDUÇÃO COM TIMOGLOBULINA VERSUS ANTICORPO MONOCLONAL ANTI - IL2R - UMA ANÁLISE PAREADA EM TRANSPLANTE RENAL COM DOADOR FALECIDOTransplante RenalImunosupressãoDoador FalecidoGlobulina AntilinfocitáriaAnticorpos MonoclonaisKidney TransplantationImmunosuppressionDeceased DonorAntilymphocyte globulinAntibodies, MonoclonalPurpose: Thymoglobulin is an important polyclonal antibody used in kidney transplantation as an induction therapy, and it has been asso- ciated to a decrease in delayed graft function and acute rejection rates. The authors used a paired kidney analysis to compare thymoglobulin with other induction therapies, in order to minimize the donor variabilility and bias. Methods: All paired kidneys from deceased donors during the period 2006-2008, where one kidney was allocated to a patient receiving thymoglobulin (group1) and its mate allocated to a pa- tient receiving anti IL-2R monoclonal antibodies (group 2) were assessed in this retrospective study. To investigate the impact of induction therapy, we investigated the delayed graft function rates (DGF), acute rejection (AR) and renal function in the first year after the transplant (Tx) in the paired kidney subjects. Results: A total of 94 Txs were investigated: mean age: 38.4 years, being 60.6 % male and with average dialysis time of 4.11 yrs. No statistically significant difference was found between both groups in relation to the recipient age, gender, HLA mismatches, PRA, cold ischemia time (CIT). Immunosuppressive protocol consisted to mofetil mycophenolate plus calcineurin inhibitors (tacrolimus in 88.3% of patients) in both groups, and steroids in 62% of patients. Deceased donor characteristics were: 63.8% male, mean age 30.9 ys, serum creatinine 1.17 mg/dl. The most important causes of death were trauma in 48.9% and cerebrovascular accident in 19.1% donors. The magnitude of renal function at 3, 6 and 12 post-Tx months and the DGF rate (56.6% vs 63.0%) were not statistically different between both groups. The rate of any AR report within 1 post-Tx year was significantly lower in the Thymo group (19.6 vs 45.7%; p = 0.008), and the incidence of CMV disease was similar in both groups (10.9 vs 15.2%; p = 0.535). Conclusion: Thymoglobulin was associated to a significant reduction in 1 yr-acute rejection rate in this cohort of paired kidneys, but without presenting a decreased DGF rate. There was no impact on renal function/CMV disease in the 1st post-Tx year.Introdução: A timoglobulina é um anticorpo policlonal utilizado na terapia de indução em transplante (Tx) renal e que tem sido associado à redução na incidência de função retardada do enxerto (DGF) e rejeição aguda. Objetivo: Comparar terapia de indução com timoglobulina versus anticorpos monoclonais anti-IL2R em uma análise pareada de transplantes renais com doador falecido. Métodos:Todos os rins pareados de doador falecido no período de 2006-2008, onde um dos rins foi alocado para um paciente recebendo timoglobulina (grupo 1) e o seu par foi alocado para um paciente recebendo anticorpo monoclonal anti-IL2R (grupo 2) foram incluídos neste estudo retrospectivo. As taxas de DGF e rejeição aguda, a função renal e a incidência de doença por citomegalovírus (CMV), no primeiro ano de transplante, foram avaliadas. Resultados: Foram incluídos 94 receptores, idade média 38,4 anos, 60,6 % do sexo masculino e tempo médio em diálise 4,11 anos. Não houve diferença estatística entre os dois grupos em relação à idade e sexo do receptor, número de mismatches HLA, anticorpos reativos contra painel (PRA) e tempo de isquemia fria (TIF). O protocolo imunossupressor inicial consistiu de micofenolato mofetil e inibidor de calcineurina (tacrolimus: 88,3%) e prednisona em 62% dos pacientes. Em relação aos doadores, 63,8% eram do sexo masculino, idade média 30,9 anos, creatinina sérica 1,17 mg/dl, causas da morte encefálica: traumatismo crânio-encefálico em 48,9% e acidente vascular cerebral em 19,1%. A função renal avaliada pela creatinina aos três, seis e doze meses pós-Tx, a incidência de DGF (56,6 vs 63,0%) e de CMV doença (10,9 vs 15,2%) não foi estatisticamente diferente entre os grupos. A taxa de rejeição aguda foi significativamente menor no grupo da timoglobulina (19,6 vs 45,7%; p = 0,008). Conclusão: A terapia de indução com timoglobulina associou-se com uma redução significativa na incidência de rejeição aguda no primeiro ano de transplante nessa coorte de receptores de rins pareados de doador falecido. Não foi detectada redução na taxa de DGF e não houve impacto na função renal/ incidência de CMV doença com o uso da timoglobulina.Associação Brasileira de Transplante de Órgãos (ABTO)2011-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://bjt.emnuvens.com.br/revista/article/view/20010.53855/bjt.v14i2.200Brazilian Journal of Transplantation; Vol. 14 No. 2 (2011); 1518-1522Brazilian Journal of Transplantation; v. 14 n. 2 (2011); 1518-15222764-1589reponame:Brazilian Journal of Transplantationinstname:Associação Brasileira de Transplante de Órgãos (ABTO)instacron:ABTOporhttps://bjt.emnuvens.com.br/revista/article/view/200/187Copyright (c) 2021 Brazilian Journal of Transplantationinfo:eu-repo/semantics/openAccessOliveira, Cláudia Maria Costa deGomes, Diego MoraisReuber, CamiloSantos, Daniela Costa de OliveiraOliveira, Maria Luisa Mattos Brito Fernandes, Paula Castelo BrancoEvangelista Júnior, JoãoEsmeraldo, Ronaldo Matos2021-09-28T14:28:53Zoai:ojs3.emnuvens.com.br:article/200Revistahttps://bjt.emnuvens.com.br/revistaONGhttps://bjt.emnuvens.com.br/revista/oaibjt@abto.org.brhttps://doi.org/10.53855/2764-15892764-1589opendoar:2021-09-28T14:28:53Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)false |
dc.title.none.fl_str_mv |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis TERAPIA DE INDUÇÃO COM TIMOGLOBULINA VERSUS ANTICORPO MONOCLONAL ANTI - IL2R - UMA ANÁLISE PAREADA EM TRANSPLANTE RENAL COM DOADOR FALECIDO |
title |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis |
spellingShingle |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis Oliveira, Cláudia Maria Costa de Transplante Renal Imunosupressão Doador Falecido Globulina Antilinfocitária Anticorpos Monoclonais Kidney Transplantation Immunosuppression Deceased Donor Antilymphocyte globulin Antibodies, Monoclonal |
title_short |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis |
title_full |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis |
title_fullStr |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis |
title_full_unstemmed |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis |
title_sort |
Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction - A paired kidney analysis |
author |
Oliveira, Cláudia Maria Costa de |
author_facet |
Oliveira, Cláudia Maria Costa de Gomes, Diego Morais Reuber, Camilo Santos, Daniela Costa de Oliveira Oliveira, Maria Luisa Mattos Brito Fernandes, Paula Castelo Branco Evangelista Júnior, João Esmeraldo, Ronaldo Matos |
author_role |
author |
author2 |
Gomes, Diego Morais Reuber, Camilo Santos, Daniela Costa de Oliveira Oliveira, Maria Luisa Mattos Brito Fernandes, Paula Castelo Branco Evangelista Júnior, João Esmeraldo, Ronaldo Matos |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Oliveira, Cláudia Maria Costa de Gomes, Diego Morais Reuber, Camilo Santos, Daniela Costa de Oliveira Oliveira, Maria Luisa Mattos Brito Fernandes, Paula Castelo Branco Evangelista Júnior, João Esmeraldo, Ronaldo Matos |
dc.subject.por.fl_str_mv |
Transplante Renal Imunosupressão Doador Falecido Globulina Antilinfocitária Anticorpos Monoclonais Kidney Transplantation Immunosuppression Deceased Donor Antilymphocyte globulin Antibodies, Monoclonal |
topic |
Transplante Renal Imunosupressão Doador Falecido Globulina Antilinfocitária Anticorpos Monoclonais Kidney Transplantation Immunosuppression Deceased Donor Antilymphocyte globulin Antibodies, Monoclonal |
description |
Purpose: Thymoglobulin is an important polyclonal antibody used in kidney transplantation as an induction therapy, and it has been asso- ciated to a decrease in delayed graft function and acute rejection rates. The authors used a paired kidney analysis to compare thymoglobulin with other induction therapies, in order to minimize the donor variabilility and bias. Methods: All paired kidneys from deceased donors during the period 2006-2008, where one kidney was allocated to a patient receiving thymoglobulin (group1) and its mate allocated to a pa- tient receiving anti IL-2R monoclonal antibodies (group 2) were assessed in this retrospective study. To investigate the impact of induction therapy, we investigated the delayed graft function rates (DGF), acute rejection (AR) and renal function in the first year after the transplant (Tx) in the paired kidney subjects. Results: A total of 94 Txs were investigated: mean age: 38.4 years, being 60.6 % male and with average dialysis time of 4.11 yrs. No statistically significant difference was found between both groups in relation to the recipient age, gender, HLA mismatches, PRA, cold ischemia time (CIT). Immunosuppressive protocol consisted to mofetil mycophenolate plus calcineurin inhibitors (tacrolimus in 88.3% of patients) in both groups, and steroids in 62% of patients. Deceased donor characteristics were: 63.8% male, mean age 30.9 ys, serum creatinine 1.17 mg/dl. The most important causes of death were trauma in 48.9% and cerebrovascular accident in 19.1% donors. The magnitude of renal function at 3, 6 and 12 post-Tx months and the DGF rate (56.6% vs 63.0%) were not statistically different between both groups. The rate of any AR report within 1 post-Tx year was significantly lower in the Thymo group (19.6 vs 45.7%; p = 0.008), and the incidence of CMV disease was similar in both groups (10.9 vs 15.2%; p = 0.535). Conclusion: Thymoglobulin was associated to a significant reduction in 1 yr-acute rejection rate in this cohort of paired kidneys, but without presenting a decreased DGF rate. There was no impact on renal function/CMV disease in the 1st post-Tx year. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://bjt.emnuvens.com.br/revista/article/view/200 10.53855/bjt.v14i2.200 |
url |
https://bjt.emnuvens.com.br/revista/article/view/200 |
identifier_str_mv |
10.53855/bjt.v14i2.200 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://bjt.emnuvens.com.br/revista/article/view/200/187 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Brazilian Journal of Transplantation info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 Brazilian Journal of Transplantation |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Transplante de Órgãos (ABTO) |
publisher.none.fl_str_mv |
Associação Brasileira de Transplante de Órgãos (ABTO) |
dc.source.none.fl_str_mv |
Brazilian Journal of Transplantation; Vol. 14 No. 2 (2011); 1518-1522 Brazilian Journal of Transplantation; v. 14 n. 2 (2011); 1518-1522 2764-1589 reponame:Brazilian Journal of Transplantation instname:Associação Brasileira de Transplante de Órgãos (ABTO) instacron:ABTO |
instname_str |
Associação Brasileira de Transplante de Órgãos (ABTO) |
instacron_str |
ABTO |
institution |
ABTO |
reponame_str |
Brazilian Journal of Transplantation |
collection |
Brazilian Journal of Transplantation |
repository.name.fl_str_mv |
Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO) |
repository.mail.fl_str_mv |
bjt@abto.org.br |
_version_ |
1836111233464401920 |